Suchergebnisse - "Li, Jing-Xin"

PubPharm (116)

1

Importance of pre-mRNA splicing and its study tools in plants

enthalten in: Advanced Biotechnology | 2024

von Liu, Y. | Do, S. | Huynh, H. | +4

2

Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above : a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos)

enthalten in: EClinicalMedicine | 2024

von Fang, Y. | Li, J. | Duangdany, D. | +19

3

Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine : two randomized, parallel-controlled, phase 2 studies

enthalten in: Expert review of vaccines | 2024

von Balgos, A. | Hannawi, S. | Chen, W. | +19

4

Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults : a multicentre, open-label phase 3 trial

enthalten in: The Lancet. Infectious diseases | 2023

von Li, J. | Hou, L. | Gou, J. | +23

CommentIn: Lancet Infect Dis. 2023 Oct;23(10):1099-1100. - PMID 37352881

5

Environmental Impact Assessment for the Use of an Orally Aerosolized Adenovirus Type-5 Vector-Based COVID-19 Vaccine in Randomized Clinical Trials

enthalten in: The Journal of infectious diseases | 2023

von Xia, X. | Tan, Z. | Wan, P. | +11

6

Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years : a randomised, double-blind, phase 2b trial

enthalten in: The Lancet. Infectious diseases | 2023

von Wu, J. | Li, J. | Liu, J. | +19

CommentIn: Lancet Infect Dis. 2023 Sep;23(9):986-987. - PMID 37216959

7

Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19

enthalten in: Human vaccines & immunotherapeutics | 2023

von Feng, J. | Wang, W. | Jin, P. | +7

8

Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac : a multicentre, open-label, phase 4, randomised trial

enthalten in: The Lancet. Respiratory medicine | 2023

von Tang, R. | Zheng, H. | Wang, B. | +24

9

Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac) : a phase 4, randomised, observer-blind, non-inferiority trial

enthalten in: The Lancet regional health. Western Pacific | 2023

von Jin, P. | Guo, X. | Gou, J. | +20

10

Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults : an open-labeled, two-centered and multi-arm randomised, phase 1 trial

enthalten in: EBioMedicine | 2023

von Gui, Y. | Li, X. | Li, J. | +20

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]